Novabridge Biosciences (NASDAQ:NBP) Insider Mark Arnold Hagler Buys 184,000 Shares of Company Stock

Novabridge Biosciences (NASDAQ:NBP – Get Free Report) insider Mark Arnold Hagler purchased 184,000 shares of Novabridge Biosciences stock in a transaction dated Wednesday, November 18th. The shares were purchased at an average cost of $0.38 per share, for a total transaction of $69,920.00. Following the completion of the transaction, the insider owned 460,000 shares of the company’s stock, valued at approximately $174,800. This represents a 66.67% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Mark Arnold Hagler also recently made the following trade(s):

  • On Tuesday, November 17th, Mark Arnold Hagler purchased 46,000 shares of Novabridge Biosciences stock. The stock was purchased at an average cost of $0.34 per share, with a total value of $15,640.00.

Novabridge Biosciences Stock Performance

NBP opened at $0.88 on Friday. Novabridge Biosciences has a 12 month low of $0.75 and a 12 month high of $5.19. The company has a fifty day simple moving average of $1.26 and a 200 day simple moving average of $1.98.

Novabridge Biosciences (NASDAQ:NBP – Get Free Report) last issued its quarterly earnings data on Thursday, August 20th. The company reported ($0.16) EPS for the quarter. On average, analysts forecast that Novabridge Biosciences will post -0.54 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on NBP shares. HC Wainwright restated a “buy” rating and issued a $9.00 price target on shares of Novabridge Biosciences in a report on Thursday, August 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Novabridge Biosciences in a research report on Thursday, August 27th. Finally, Wall Street Zen upgraded Novabridge Biosciences from a “strong sell” rating to a “sell” rating in a report on Tuesday, September 15th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Novabridge Biosciences currently has an average rating of “Hold” and an average price target of $9.00.

View Our Latest Research Report on NBP

About Novabridge Biosciences

(Get Free Report)

Novabridge Biosciences (NASDAQ: NBP) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel biologic medicines, primarily for the treatment of cancer. Its research and development activities center on immunotherapies designed to activate the immune system or target specific proteins associated with tumor growth and survival. The company’s pipeline has included investigational antibody-based therapies such as givastomig, a bispecific antibody designed to target Claudin 18.2 and stimulate an immune response through 4-1BB, as well as other programs directed at tumor-associated and immune-regulatory targets.

Featured Articles

Insider Buying and Selling by Quarter for Novabridge Biosciences (NASDAQ:NBP)

Receive News & Ratings for Novabridge Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novabridge Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.